Atoltivimab
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA) -approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection[1].
Product Specifications
CAS Number
2135632-29-8
Product Name Alternative
REGN3470
UNSPSC
12352203
Target
Filovirus
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/atoltivimab.html
Purity
98.66
Solubility
10 mM in DMSO
Smiles
[Atoltivimab]
Molecular Weight
(145.1 kDa)
References & Citations
[1]Saxena D, et al. Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus. Drugs Today (Barc) . 2021 Aug;57 (8) :483-490.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
EBOV
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
DXC59050-01 50 mg
Ethyl 2- (chloromethyl) -4- (trifluoromethyl) -1,3-oxazole-5-carboxylate
Sign In for Pricing
View Details DXC59050-02 0.5 g
Ethyl 2- (chloromethyl) -4- (trifluoromethyl) -1,3-oxazole-5-carboxylate
Sign In for Pricing
View Details